GITR agonist enhances vaccination responses in lung cancer

Keyphrases

• Tumor 100%
• Lung Cancer 100%
• Vaccine Response 100%
• Natural Killer Cells 60%
• T Cells 60%
• Therapeutic Vaccination 60%
• Immune Response 40%
• Chemokines 40%
• Natural Killer T 40%
• Treatment Group 20%
• Interleukin-12 (IL-12) 20%
• Tumor Growth 20%
• Monotherapy 20%
• Reduced Expression 20%
• Tumor Cells 20%
• Cell Activity 20%
• TNF Receptor 1 (TNFR1) 20%
• Immune Tolerance 20%
• Antigen-presenting Cells 20%
• Inflammatory Response 20%
• Immune Evasion 20%
• Murine Lung 20%
• Anti-tumor Response 20%
• Tumor Burden 20%
• Tumor Microenvironment 20%
• Antiangiogenic 20%
• Agonistic Antibody 20%
• Tumor Cell Apoptosis 20%
• Lymphocyte Activity 20%
• Angiogenic 20%
• Immune Memory 20%
• Rechallenge 20%
• Endothelial Markers 20%
• Tumor-bearing Mice 20%
• Tumor Rejection 20%
• Cytolysis 20%
• IL-10 Levels 20%
• Cleaved caspase-3 20%
• Cell Depletion 20%
• MecA 20%
• Agonist Antibody 20%
• Immune Cell Function 20%
• Lung Cancer Model 20%
• Immune-tolerant 20%

Immunology and Microbiology

• Natural Killer Cell 100%
• T Cell 100%
• Agonist 100%
• Immunology 100%
• Tumor Cell 66%
• Immune Response 66%
• Chemokine 66%
• Tumor Necrosis Factor 33%
• Cell Activity 33%
• Immunocompetent Cell 33%
• Cell Function 33%
• Immune Tolerance 33%
• Immune Evasion 33%
• Caspase 33%
• Tumor Necrosis Factor Receptor 33%
• Antigen Presenting Cell 33%
• Immunity 33%
• Interleukin 10 33%
• Tumor Volume 33%
• Immunological Memory 33%
• Tumor Rejection 33%
• Cell Marker 33%
• Cytolysis 33%